Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy
Cancer Immunology, Immunotherapy · 02.07.2024 · 73 (9)
DOI: 10.1007/s00262-024-03757-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 02.07.2024. Verfasst von Zongliang Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Inn…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation.
Abstract (Originalsprache)
Recent studies have indicated that combining oncolytic viruses with CAR-T cells in therapy has shown superior anti-tumor effects, representing a promising approach. Nonetheless, the localized delivery method of intratumoral injection poses challenges for treating metastatic tumors or distal tumors that are difficult to reach. To address this obstacle, we employed HSV-1-infected CAR-T cells, which systemically delivery HSV into solid tumors. The biological function of CAR-T cells remained intact after loading them with HSV for a period of three days. In both immunocompromised and immunocompetent GBM orthotopic mouse models, B7-H3 CAR-T cells effectively delivered HSV to tumor lesions, resulting in enhanced T-cell infiltration and significantly prolonged survival in mice. We also employed a bilateral subcutaneous tumor model and observed that the group receiving intratumoral virus injection exhibited a significant reduction in tumor volume on the injected side, while the group receiving intravenous infusion of CAR-T cells carrying HSV displayed suppressed tumor growth on both sides. Hence, CAR-T HSV cells offer notable advantages in the systemic delivery of HSV to distant tumors. In conclusion, our findings emphasize the potential of CAR-T cells as carriers for HSV, presenting significant advantages for oncolytic virotherapy targeting distant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University,…
- Department of Ophthalmology, West China Hospital, Sichuan University, West China Medical School, Chengdu, 610041, Sichuan, China.
- Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, Sichuan, China.
- Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, Sichuan, China. zhlxlll@163.com.
- Department of Neurosurgery, Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan, 753000, Ningxia, China. zhlxlll@163.com.
- Department of Neurosurgery, Mianyang Central Hospital, Mianyang, 621000, Sichuan, China. zhlxlll@163.com.
Förderung
- National Natural Science Foundation of China
- the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation
Zitieren
APA
Zhang, Z., Yang, N., Xu, L., Lu, H., Chen, Y., Wang, Z., Lu, Q., Zhong, K., Zhu, Z., Wang, G., Li, H., Zheng, M., Zhou, L., & Tong, A. (2024). Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy. Cancer Immunology, Immunotherapy, 73(9). https://doi.org/10.1007/s00262-024-03757-8
Vancouver
Zhang Z, Yang N, Xu L, Lu H, Chen Y, Wang Z, et al. Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy. Cancer Immunology, Immunotherapy. 2024;73(9). doi:10.1007/s00262-024-03757-8
BibTeX
@article{Zhang2024,
author = {Zhang, Zongliang and Yang, Nian and Xu, Long and Lu, Huaqing and Chen, Yongdong and Wang, Zeng and Lu, Qizhong and Zhong, Kunhong and Zhu, Zhixiong and Wang, Guoqing and Li, Hexian and Zheng, Meijun and Zhou, Liangxue and Tong, Aiping},
title = {Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {73},
number = {9},
doi = {10.1007/s00262-024-03757-8}
}
EUVIMED